id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-N-2855-0001,FDA,FDA-2022-N-2855,"Mylan Institutional, Inc.; Withdrawal of Approval of a New Drug Application for SULFAMYLON® (Mafenide Acetate, USP) Powder for 5% Topical Solution",Notice,Withdrawal,2022-11-30T05:00:00Z,2022,11,2022-11-30T05:00:00Z,,2022-11-30T14:46:10Z,2022-26057,0,0,090000648550a1ec